Search Results 121-130 of 838 for 자격증위조
... . VID-20128183. Home; Brightcove-Arthroscopic repair of rotator cuff injury-Single. Have 2X the impact! Give Today. Make a gift that can go twice as far ...
The objective of this study is to evaluate the efficacy and safety of upadacitinib compared to placebo as induction therapy in participants with moderately and ...
Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
This study will examine the effect intravenously administered rigosertib has on the relationship between bone marrow blasts response and overall survival in ...
Will rigosertib, with an aggressive infusion dose, improve overall survival of MDS better than the treatments available today? Participation eligibility.
About this study. Study CRB-402 is a 2-part, non-randomized, open label, multi-site Phase 1 study of bb21217 in adults with relapsed/refractory multiple ...
The purpose of the study is to evaluate the microbiological response and clinical effectiveness of SPR720 compared with placebo in participants with ...
About this study. Trudi will give us the data points to address residents and consultants skill level and areas of weakness during endoscopic sinus ...
Different dose regimens will be evaluated. Different methods of administration may be evaluated. The pharmacokinetics, pharmacodynamic effects, biomarkers of ...
Monoclonal antibodies, such as bevacizumab and ipilimumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
The deadline to have twice the impact to advance healthcare research is May 15.